Return to homepagePandemic Pact

EPICOS- Clinical Trial for the Prevention of Coronavirus Infection in Healthcare

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_01112

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    Julia del Amo Valer

  • Research Location

    Spain

  • Lead Research Institution

    FUNDACIÇÿN ESTATAL, SALUD, INFANCIA Y BIENESTAR SOCIAL, F.S.P.

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)Older adults (65 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Randomized clinical trial to evaluate the efficacy of the daily single tablet dose of Tenofovir (TDF) (245 mg) Emtricitabine (FTC) (200 mg), daily single tablet dose of Hydroxychloroquine (HC) (200 mg), and daily dose of TDF (245 mg) FTC (200 mg) plus CH (200 mg) or placebo, for 12 weeks in: (1) decreased incidence of symptomatic disease and 2) decreased clinical severity of coronavirus infection (COVID -19) in hospital health personnel aged 18 to 65 years exposed to coronavirus infection (COVID-19) in Spain.